listed · IPO · BSE SME · listed 18 May 2026

GOLDLINE PHARMACEUTICAL LIMITED

Raised ₹11.61 Cr at ₹43 per share.

+32.0%

listing-day move

Issue price

₹43

Issue size

₹11.61 Cr

Listing-day close

₹56.77

Return since listing

+12.65%

Company research

Source: Tijori Finance · third-party enrichment

About the company

Goldline Pharmaceuticals Ltd., established in 2021, markets pharmaceutical and wellness products under the “Goldline” brand through third-party manufacturing partnerships. The company focuses on quality-driven distribution, healthcare supply solutions, and efficient pharmaceutical procurement services.

Financials (₹ crore)

Period	Revenue	PAT	Debt
Mar 2023	19.85 Cr	0.26 Cr	10.83 Cr
Mar 2024	23.57 Cr	1.81 Cr	11.13 Cr
Mar 2025	28.06 Cr	2.83 Cr	11.03 Cr

Revenue mix

Goldline Pharma 46.6%

Goldline Cardinal 26.5%

Revenue from Material Supply & Procurement Suppor 11.6%

Goldline InLife 10.0%

Goldline Aayushman 3.8%

Goldline Wellness 1.6%

Peer comparison

Company	Mkt cap (Cr)	Revenue	PAT	P/E	P/B
GOLDLINE	44	28.06 Cr	2.83 Cr	15.63	—
MONOPHARMA	22	168 Cr	3.09 Cr	7	—
CBPL	33	86.72 Cr	0.86 Cr	10.9	—

Exchange filings

Fields captured from NSE and BSE

Issue information

Symbol: GPL03

Data sources: BSE , MONEYCONTROL . Data quality clean.